Businessfrom24/7 Wall St.6 days agoAbbVie Gets JPMorgan Buying Opportunity Call With $260 Price Target Amid Competitive ConcernsJPMorgan maintains an Overweight rating on AbbVie, viewing recent stock pullback as a buying opportunity with a $260 price target.
Businessfrom24/7 Wall St.1 week agoHigh Yield vs. Sustainable Growth: Why AbbVie's Dividend Beats Pfizer's Despite the Lower PayoutAbbVie shows strong growth with Skyrizi, while Pfizer struggles with declining COVID revenue and sustainability concerns in dividends.
from24/7 Wall St.3 months agoBusiness2026 Rate Cuts Coming as Inflation Drops: 5 Quality Dividend Stocks to Buy Now
from24/7 Wall St.3 months agoBusiness2026 Rate Cuts Coming as Inflation Drops: 5 Quality Dividend Stocks to Buy Now
Healthcarefrom24/7 Wall St.4 months agoThis Dividend Pharma Giant Yielding 2.9% Just Got a Big Vote of ConfidenceHealthcare shows signs of stabilization and potential rebound driven by easing policy risks, clearer earnings, and increased M&A, with AbbVie as a dividend-led candidate.
from24/7 Wall St.5 months agoBusinessI have invested in dividends for 11 years-These income machines pay me every quarter without a hitch
from24/7 Wall St.5 months agoBusinessI have invested in dividends for 11 years-These income machines pay me every quarter without a hitch
Medicinefrom24/7 Wall St.6 months agoTop Dividend Stocks Poised for Explosive Growth in 2026 (ABBV, GD, RGR)AbbVie shows strong stock performance near analyst targets, offers a 2.79% dividend yield, and markets a novel C‑MET–targeting oncology drug, Emrelis.
